stoxline Quote Chart Rank Option Currency Glossary
  
Seres Therapeutics, Inc. (MCRB)
0.781  0.001 (0.1%)    03-28 11:31
Open: 0.787
High: 0.7982
Volume: 1,156,672
  
Pre. Close: 0.7802
Low: 0.7616
Market Cap: 118(M)
Technical analysis
2024-03-28 11:18:28 AM
Short term     
Mid term     
Targets 6-month :  1.22 1-year :  1.44
Resists First :  1.04 Second :  1.24
Pivot price 0.79
Supports First :  0.73 Second :  0.6
MAs MA(5) :  0.77 MA(20) :  0.87
MA(100) :  1.1 MA(250) :  2.92
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  12.6 D(3) :  11.5
RSI RSI(14): 37.4
52-week High :  6.86 Low :  0.73
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ MCRB ] has closed above bottom band by 40.8%. Bollinger Bands are 47.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.8 - 0.81 0.81 - 0.81
Low: 0.74 - 0.75 0.75 - 0.75
Close: 0.77 - 0.78 0.78 - 0.79
Company Description

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-155, a cultivated bacteria microbiome drug, which is Phase Ib clinical trial to reduce incidences of gastrointestinal infections, bloodstream infections, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. In addition, the company engages in the development of SER-287 and SER-301 that are in Phase Ib to treat ulcerative colitis; SER-401 for patients with metastatic melanoma; and SER-262 to treat Clostridioides difficile infection. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Headline News

Thu, 28 Mar 2024
Seres Therapeutics (NASDAQ:MCRB) Stock Price Crosses Below 50-Day Moving Average of $1.03 - Defense World

Thu, 28 Mar 2024
Seres Therapeutics (NASDAQ:MCRB) Stock Price Crosses Below 50-Day Moving Average of $1.03 - MarketBeat

Sat, 23 Mar 2024
Benign Growth For Seres Therapeutics, Inc. (NASDAQ:MCRB) Underpins Stock's 30% Plummet - Simply Wall St

Tue, 12 Mar 2024
Institutional owners may take dramatic actions as Seres Therapeutics, Inc.'s (NASDAQ:MCRB) recent 25% drop adds to ... - Simply Wall St

Thu, 07 Mar 2024
Seres Therapeutics, Inc. (NASDAQ:MCRB) Q4 2023 Earnings Call Transcript - Yahoo Finance

Tue, 05 Mar 2024
Seres Therapeutics, Inc. (MCRB) Q4 2023 Earnings Call Transcript - Seeking Alpha

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 151 (M)
Held by Insiders 1.1874e+008 (%)
Held by Institutions 5.6 (%)
Shares Short 15,590 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -1.0174e+008
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin -90.1 %
Operating Margin -61 %
Return on Assets (ttm) 759.3 %
Return on Equity (ttm) -19.1 %
Qtrly Rev. Growth 1.2633e+008 %
Gross Profit (p.s.) -41.15
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth -0.9 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -117 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow -5.36
Stock Dividends
Dividend 0
Forward Dividend 1.61e+007
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android